DOCSLIB.ORG

No. 166 Poisons POISONS 605 ORDER

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
No. 166 Poisons POISONS 605 ORDER No. 166 Poisons 605 1969. No. 166 [C] POISONS ORDER, DATED 23RD JUNE 1969. MADE BY THE MINISTER OF HOME AFFAIRS UNDER SECTION 26A(6) OF TIlE MEDICINES, PHARMACY AND POISONS ACT (NORTHERN IRELAND) 1945. Whereas the Poisons Board, constituted in accordance with Section 26 of the Medicines, Pharmacy and Poisons Act (NoI'thern Ireland) 1945(a), has recommended to me th!;lt the list of substances which are to be treated as poisons for the purposes of the Pharmacy and Poisons Acts (Northern Ireland) 1925 to 1955(b) and known as "the Poisons Schedule" for the purposes of those Aot& should be amended so that certain additional substances should be included in rart I of the said schedule (which Part consists of those Poisons which, subject to the provisions of the said Acts, are not to be sold except by a person who is an authorised seller of poisons). Now, therefore, I, the Right Honourable R. W. Porter, Q.C., Minister of Home . Affairs, in exercise of the powers conferred on me by Section 26A(6) of the Medicin~s, Pharmacy and Poisons Act (Northern Ireland) 1945 and of all othet powers enabling me in that behalf do hereby order as follows: Citation and Commencement 1. This Order may be cited as the Poisons List Order (Northern Ireland) . 1969 and shall come into operation on 1st September 1969. Amendments 2. Part I of the "Poisons Schedule"(c) shall be amended and varied in the manner specified in the First Schedule to this Order .and ·accordingly the list of substances which are to be treated as poisons for the purposes of the Pharmacy and Poisons Acts (Northern Ireland) 1925 to 1967(d) shall be as set out in the Second Schedule. Dated this 23rd day of June 1969. R.W. Porter, Minister of Home Affairs for Northern Ireland. (a) 1945. C. 9. (b) 15 & 16 Geo. 5. c. 8 (N.I.) & 1955. c.. 3.i. (c) See the Second Schedule to the Poisons List Order (N.J.) 1'96~· (S.R. &. O. 1968, No. 155). Cd) i967.c. 12 (NoI.). 606 Poisons No. 166' FIRST SCHEDULE Amendments and Variations in the Poisons Schedule 1. In Part I of the Poisons Schedule- (a) there .shall be inserted,at the appropriate points in the schedule therein; set out in .alphabetical order the following items, that is to say:- "Aminorex' its salts" "Clorprenaiine; 'its salts" "4-Cyano-2-dimethylamino-4, 4-diphenylbutane;. its salts" "4-Cyano-l-methyl-4-phenylpiperidine; its salts" "Ethylnoradrena~ne; its salts" "Iprindole; its 'salts" "Isoaminile; its salts" "Isoethatine' its salts" "Isoprenalin~; its salts" "Methoxyphenamine; its salts" "Methylamino):leptane; its salts" "2-Methyl-3-morpholino-l, I-diphenylpropanecarboxylic acid; its salts; its esters; their salts" "Mitopodozide; its salts" "Orciprenaline; its salts" "Oxytocins, natural and synthetic" "4-Phenylpiperidine':4-catboxy!ic acid ethyl ester; its salts" "Podophyllum resin" "Procainamide; its salts" "Thiocarlide' its salts" "Vasopressir:s,natural ariel synthetic"; (b) in the items beginning with the following words, that is to say:­ "Desomorphine" "Dihydrocodeine" "Dimepheptap.ol" "Ethylmorphine" "Hydromorphinol" "Hydroxypethidine" "Ketobemidone" "Levophenacylmorphan" "Levorphanol" "Metazocine" "Methyldesol'Phine" "Methyldihydromorphine" "Metopon" "Norcodeine" "Norlevorphanol" "NormOljphine" "Oxymorphone" "Phenazocine" "Phenomorphan" "Phenoperidine" "Pholcodine" "Racemol'Phan" there shall in each case be added at the end -the words "its esters and ,ethers; their salts"; (c) in the items' beginning with the following words, that is to say:­ "Dihydromorphine" "Hydromol'Phone" , "Oxycodone" ther.e shall in each case be added at the end the words "its ethers; their saits"; No. 166 PoiSOll$ 607 (d) for the heading beginning with the word "Alkaloiqs" there shall be substituted the h~ading "Alkaloids, the following; their quaternary compounds; any salt, sImple or complex, or any substance falling within the following:-" and under that heading- (i) for the item "Codeine" there shall be substituted the item "Codeine; its esters and ethers"; (ii) for the item "Ecgonine; its esters" there shall be substituted the item "Ecgonine; its esters and ethers"; (iii} in the item beginning with the word "Ergot" the words "apy salt of any substance falling within this item" (which refer to substances comprised within the heading substituted as aforesaid) shall be omitted; (iv) for the item "Morphine" there shall be substituted the item "Morphine; its esters and ethers"; (e) for the item "Mescaline; its salts" there shall be substituted the item "Mescaline and other derivatives of phenethylamine fo:r:med by substitution in the aromatic ring; their salts"; (f) after the item beginning with the word "Methylpentynol" there shall be inserted the item "a-Methylpl+enethylamine, B-methylphenethylamine and a-ethylphenethylamiile; any synthetic compound structurally derived from any of those substances by substitution in the aliphatic part or by ring closure therein (or by both such substitution and such closure) or by substitution in the aromatic ring (with or without substitution at the nitrogen atom), except ephedrine and its optical isomers, N-substituted derivatives, fenfiuramine, hydroxyamphet8Jmine, methoxyphenamine, phenylpropanolamine, pholedrine and prenylamine; any salt of any substance falling within this item", and accordingly the item beginning with the word "B-Aminopropylbenzene" (which refers to substances comprised within the item inserted as aforesaid) shall be omitted; (g) the item beginning with the word "Oxycinchoninic acid" shall be omitted, and after the item geginning with the word "Hydromorphone" there shall be inserted the item "Hydroxycinchoninic acids; derivatives of; their sla1ts; their esters" (being a different description of the same substances); (h) for the item beginning with the words "Phenylcinchoninic acid" there shall be substituted the item "2-Phenylcinchoninic acid, 2-salicylcinchoninic acid; their saIts; their esters" (being a different description of the same substances); (i) in the items beginning with the following words, that is to say:.­ "Dihydrocodeinone" "Thebacon" the words "its esters; their salts" (which ate superfluous) shall in each case be omitted. SECOND SCHEDULE . The Poisons Schedule PART I Acetanilide; alkyl acetaIiiIides Acetohexamide .. .... Acetorphine;· its salts; its esters and ethers; their salts Acety lcarbromal Acetyldihydrocodeine; its· salts Alcuronitim chloride AlkaIifiuorides other than those specified in Part II of this Schedule Mkaloids, the follOWIng; ,their quaternary compounds; any salt, simple or comple~ of any substance falling within the following:­ Aconite, alkaloids of Atropine Belladonna, alkaloids of Brucine Calabar bean, alkaloids of Coca, alkaloids of Cocaine 608 Poisons No.· 166 Codeine; its esters and ethers Colchicnm, alkaloids of Coniine Cotarnine Curare, alkaloids of; curare bases Ecgonine; its esters and ethers Emetine Ephedra, alkaloids of Ergot, alkaloids of, whether hydrogenated or not; their homologues Gelsemium,. a~aloids of Homatropine Hyoscine Hyoscyamine Jaborandi, alkaloids of Lobelia, alkaloids of Morphine; its esters and ethers· Papaverine Pomegranate, alkaloids of Quebracho, alkaloids of, other than the alkaloids of red quebracho Rauwolfia, alkaloids of; their qerivatives Sabadilla, alkaloids of Solanaceous alkaloids not otherwise included in this Schedule Staves acre, alkaloids of . Strychnine Thebaine Veratrum, alkaloids of Y ohimba, alkaloids of Allylisopropylacetylurea Allylprodine; its salts . Alphameprodine; its salts Alphaprodine; its salts Amidopyrine; its salts; amidopyrine sulphona:tes;' tbeir salts Amino-alcohols esterified with benzoic acid, phenylacetic acid, phenylpropionic acid, cinnamic acid or the derivatives of these acids; their salts . p-Aminobenzenesulphonamide; its 'salts; derivatives of p-aminobenzenesulphona· mide having any of the hydrogen atoms of the p-amino gtoupor of the sulphonamide group substituted by another radical; their salts p-Aminobenzoic acid, esters of; their salts Aminorex; its salts Amitriptyline; its salts Amyl nitrite Androgenic, oestrogenic and proges,tational substance, tbe following·::....... Benzoestrol Derivatives of stilbene, dibenzyl or naphthalene with oestrogenic activity; their esters Steroid compounds with androgenic or oestrogenic or progestational activity; their esters . Anileridine; its salts Anti-histamine substances, the following; their salts;. their molecular compounds.:-- Antazoline . Bromodiphenhydramine Buclizine Carbinoxamine ChlorcycliZine Chlorpheniramine Cinnarizine Clemizole Cyc1izine Cyproheptadine 3-Di-n-butylaminomethyl-4, 5, 6-trihydroxyphthalide Diphenhydramine Diphenylpyraline 'w r ,,~ • Doxylamine , iii i.,.' , Isothipendyl .: • >-'" > "'~ f", Meb)1ydrolin Meclozine Phenindamine Pheniramlne . Phimyltoloxamine,;i ..• ,;.,." .. ::;' ' .. Promethazine ,.', pyrrobutamine Thenalidme Toipropamine Triprolidine Substances being tetra-substituted N derivatives of etliy'lepedi~mip.e, or '. '. ". propy'~enep.i,amine, , .," .. , .' , Antimony, chlofides b.~; ef(cept .anfimony 'trichlorilie; oxides of i).ntimony; $tilphides of antimony; antimonfl.t~; lj.nfim6nites;. Ol:gahiC' comp'ounds 9f antimony Apiol ami oil of parsley.. , .. , ":,,.' .,'", : . ...' . '., .. Apomorphine; its salts' '" ,'. , .. ,' "., .., '" . Arseni~al s~p~t~JtC~~l t!?-e f.9Uowjn~, eXc~pt t)1os~ s~ecitied ~Il: Part li of~)1is Schedlll~ : halides of arsemc; oXIdes of'arsemc; arsenates; arseIiItes; organIc COmllOu:Q,ds of arsenic . " : , _, '. • ". i· Azacyclonol; its salts ~~j" ~., ,a~::. '.~:..' :~.~l::~ . .'1"\~ Barbituric
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn Et Al
    US 2004O224012A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn et al. (43) Pub. Date: Nov. 11, 2004 (54) TOPICAL APPLICATION AND METHODS Related U.S. Application Data FOR ADMINISTRATION OF ACTIVE AGENTS USING LIPOSOME MACRO-BEADS (63) Continuation-in-part of application No. 10/264,205, filed on Oct. 3, 2002. (76) Inventors: Pichit Suvanprakorn, Bangkok (TH); (60) Provisional application No. 60/327,643, filed on Oct. Tanusin Ploysangam, Bangkok (TH); 5, 2001. Lerson Tanasugarn, Bangkok (TH); Suwalee Chandrkrachang, Bangkok Publication Classification (TH); Nardo Zaias, Miami Beach, FL (US) (51) Int. CI.7. A61K 9/127; A61K 9/14 (52) U.S. Cl. ............................................ 424/450; 424/489 Correspondence Address: (57) ABSTRACT Eric G. Masamori 6520 Ridgewood Drive A topical application and methods for administration of Castro Valley, CA 94.552 (US) active agents encapsulated within non-permeable macro beads to enable a wider range of delivery vehicles, to provide longer product shelf-life, to allow multiple active (21) Appl. No.: 10/864,149 agents within the composition, to allow the controlled use of the active agents, to provide protected and designable release features and to provide visual inspection for damage (22) Filed: Jun. 9, 2004 and inconsistency. US 2004/0224012 A1 Nov. 11, 2004 TOPCAL APPLICATION AND METHODS FOR 0006 Various limitations on the shelf-life and use of ADMINISTRATION OF ACTIVE AGENTS USING liposome compounds exist due to the relatively fragile LPOSOME MACRO-BEADS nature of liposomes. Major problems encountered during liposome drug Storage in vesicular Suspension are the chemi CROSS REFERENCE TO OTHER cal alterations of the lipoSome compounds, Such as phos APPLICATIONS pholipids, cholesterols, ceramides, leading to potentially toxic degradation of the products, leakage of the drug from 0001) This application claims the benefit of U.S.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • Transdermal Drug Delivery Device Including An
    (19) TZZ_ZZ¥¥_T (11) EP 1 807 033 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61F 13/02 (2006.01) A61L 15/16 (2006.01) 20.07.2016 Bulletin 2016/29 (86) International application number: (21) Application number: 05815555.7 PCT/US2005/035806 (22) Date of filing: 07.10.2005 (87) International publication number: WO 2006/044206 (27.04.2006 Gazette 2006/17) (54) TRANSDERMAL DRUG DELIVERY DEVICE INCLUDING AN OCCLUSIVE BACKING VORRICHTUNG ZUR TRANSDERMALEN VERABREICHUNG VON ARZNEIMITTELN EINSCHLIESSLICH EINER VERSTOPFUNGSSICHERUNG DISPOSITIF D’ADMINISTRATION TRANSDERMIQUE DE MEDICAMENTS AVEC COUCHE SUPPORT OCCLUSIVE (84) Designated Contracting States: • MANTELLE, Juan AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Miami, FL 33186 (US) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • NGUYEN, Viet SK TR Miami, FL 33176 (US) (30) Priority: 08.10.2004 US 616861 P (74) Representative: Awapatent AB P.O. Box 5117 (43) Date of publication of application: 200 71 Malmö (SE) 18.07.2007 Bulletin 2007/29 (56) References cited: (73) Proprietor: NOVEN PHARMACEUTICALS, INC. WO-A-02/36103 WO-A-97/23205 Miami, FL 33186 (US) WO-A-2005/046600 WO-A-2006/028863 US-A- 4 994 278 US-A- 4 994 278 (72) Inventors: US-A- 5 246 705 US-A- 5 474 783 • KANIOS, David US-A- 5 474 783 US-A1- 2001 051 180 Miami, FL 33196 (US) US-A1- 2002 128 345 US-A1- 2006 034 905 Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
    [Show full text]
  • Public Use Data Tape Documentation 1992 National Ambulatory Medical Care Survey
    Public Use Data Ta~e Documentation 1992 National Ambulatory Medical Care Survey From the CENTERS FOR DISEASE CONTROL AND PREVENTION/Nutional Center for Health Stdklics -—..—=-.=-=.-.‘,.- . ----. - . .- -,-- -.-- .--.,. -’ ‘ --- - –.--.------ ,-:-.-,J ----- ---------- ---P ------.-->- — .. ..- --. : _ U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Publlc Health Service Centers for Disease Control and Prevention National Center for Health Statistics CDCcE141EmFonmEUEcoumoL WMEmmm Public Use Data Tape Documentation 1992 National Ambulatory Medical Care Survey U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Centers for Disease Control and Prevention National Center for Health .SJatistics Hyattsville, Maryland November 1994 299 2 NAMcs MICRO-DATA TAPE Docum NTATION PAGE 1 ABSTRACT This material provides documentation for users of the Micro-Data tapes of the National Ambulatory Medical Care Suney (NAMCS) conducted by the National Center for Health Statistics. Section I, “Description of the National Ambulatory Medical Care Sumey,” includes information on the scope of the amm.rey,the sample, field activities, data collection procedures, medical coding procedures, population estimates, and sampling errors. Section II provides technical detaile of the tape (number of tracks, record length, etc.), and a detailed description of the contents of each data record by location. Section III contains marginal data or estimates for each item on the data record in Section II. The appendixes contain santplingerrors, instructions and definitions for completing the Patient Record Form, and list~ of codes used in the survey. TABLE OF CONTENTS PAGE I. Description of the National Ambulatory Medical Care SuNey 2-14 Distribution of physicians (Table I) 4 Population Figures (Table II) 6 Patient Log and Patient Record Form (Figure 1) 8 References 14 II.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0159073 A1 De Juan Et Al
    US 20110159073A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0159073 A1 de Juan et al. (43) Pub. Date: Jun. 30, 2011 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA A6F 2/00 (2006.01) (US); Signe E. Varner, Los (52) U.S. Cl. ........................................................ 424/427 Angeles, CA (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Featured is a method for instilling one or more bioactive (21) Appl. No.: 12/981,038 agents into ocular tissue within an eye of a patient for the treatment of an ocular condition, the method comprising con (22) Filed: Dec. 29, 2010 currently using at least two of the following bioactive agent delivery methods (A)-(C): (A) implanting a Sustained release Related U.S. Application Data delivery device comprising one or more bioactive agents in a (63) Continuation of application No. 1 1/175,850, filed on posterior region of the eye so that it delivers the one or more Jul. 5, 2005, now abandoned. bioactive agents into the vitreous humor of the eye; (B) instill ing (e.g., injecting or implanting) one or more bioactive (60) Provisional application No. 60/585,236, filed on Jul. 2, agents Subretinally; and (C) instilling (e.g., injecting or deliv 2004, provisional application No. 60/669,701, filed on ering by ocular iontophoresis) one or more bioactive agents Apr. 8, 2005. into the vitreous humor of the eye. Patent Application Publication Jun. 30, 2011 Sheet 1 of 22 US 2011/O159073 A1 Patent Application Publication Jun.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2002/0102215 A1 100 Ol
    US 2002O102215A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2002/0102215 A1 Klaveness et al. (43) Pub. Date: Aug. 1, 2002 (54) DIAGNOSTIC/THERAPEUTICAGENTS (60) Provisional application No. 60/049.264, filed on Jun. 6, 1997. Provisional application No. 60/049,265, filed (75) Inventors: Jo Klaveness, Oslo (NO); Pal on Jun. 6, 1997. Provisional application No. 60/049, Rongved, Oslo (NO); Anders Hogset, 268, filed on Jun. 7, 1997. Oslo (NO); Helge Tolleshaug, Oslo (NO); Anne Naevestad, Oslo (NO); (30) Foreign Application Priority Data Halldis Hellebust, Oslo (NO); Lars Hoff, Oslo (NO); Alan Cuthbertson, Oct. 28, 1996 (GB)......................................... 9622.366.4 Oslo (NO); Dagfinn Lovhaug, Oslo Oct. 28, 1996 (GB). ... 96223672 (NO); Magne Solbakken, Oslo (NO) Oct. 28, 1996 (GB). 9622368.0 Jan. 15, 1997 (GB). ... 97OO699.3 Correspondence Address: Apr. 24, 1997 (GB). ... 9708265.5 BACON & THOMAS, PLLC Jun. 6, 1997 (GB). ... 9711842.6 4th Floor Jun. 6, 1997 (GB)......................................... 97.11846.7 625 Slaters Lane Alexandria, VA 22314-1176 (US) Publication Classification (73) Assignee: NYCOMED IMAGING AS (51) Int. Cl." .......................... A61K 49/00; A61K 48/00 (52) U.S. Cl. ............................................. 424/9.52; 514/44 (21) Appl. No.: 09/765,614 (22) Filed: Jan. 22, 2001 (57) ABSTRACT Related U.S. Application Data Targetable diagnostic and/or therapeutically active agents, (63) Continuation of application No. 08/960,054, filed on e.g. ultrasound contrast agents, having reporters comprising Oct. 29, 1997, now patented, which is a continuation gas-filled microbubbles stabilized by monolayers of film in-part of application No. 08/958,993, filed on Oct.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Pharmacy Data Management Drug Exception List
    Pharmacy Data Management Drug Exception List Patch PSS*1*127 updated the following drugs with the listed NCPDP Multiplier and NCPDP Dispense Unit. These two fields were added as part of this patch to the DRUG file (#50). Please refer to the Release notes for ePharmacy/ECME Enhancements for Pharmacy Release Notes (BPS_1_5_EPHARMACY_RN_0907.PDF) on the VistA Documentation Library (VDL). The IEN column reflects the IEN for the VA PRODUCT file (#50.68). The ePharmacy Change Control Board provided the following list of drugs with the specified NCPDP Multiplier and NCPDP Dispense Unit values. This listing was used to update the DRUG file (#50) with a post install routine in the PSS*1*127 patch. NCPDP File 50.68 NCPDP Dispense IEN Product Name Multiplier Unit 2 ATROPINE SO4 0.4MG/ML INJ 1.00 ML 3 ATROPINE SO4 1% OINT,OPH 3.50 GM 6 ATROPINE SO4 1% SOLN,OPH 1.00 ML 7 ATROPINE SO4 0.5% OINT,OPH 3.50 GM 8 ATROPINE SO4 0.5% SOLN,OPH 1.00 ML 9 ATROPINE SO4 3% SOLN,OPH 1.00 ML 10 ATROPINE SO4 2% SOLN,OPH 1.00 ML 11 ATROPINE SO4 0.1MG/ML INJ 1.00 ML 12 ATROPINE SO4 0.05MG/ML INJ 1.00 ML 13 ATROPINE SO4 0.4MG/0.5ML INJ 1.00 ML 14 ATROPINE SO4 0.5MG/ML INJ 1.00 ML 15 ATROPINE SO4 1MG/ML INJ 1.00 ML 16 ATROPINE SO4 2MG/ML INJ 1.00 ML 18 ATROPINE SO4 2MG/0.7ML INJ 0.70 ML 21 ATROPINE SO4 0.3MG/ML INJ 1.00 ML 22 ATROPINE SO4 0.8MG/ML INJ 1.00 ML 23 ATROPINE SO4 0.1MG/ML INJ,SYRINGE,5ML 5.00 ML 24 ATROPINE SO4 0.1MG/ML INJ,SYRINGE,10ML 10.00 ML 25 ATROPINE SO4 1MG/ML INJ,AMP,1ML 1.00 ML 26 ATROPINE SO4 0.2MG/0.5ML INJ,AMP,0.5ML 0.50 ML 30 CODEINE PO4 30MG/ML
    [Show full text]
  • Medicines Regulations 1984 (SR 1984/143)
    Reprint as at 1 December 2017 Medicines Regulations 1984 (SR 1984/143) David Beattie, Governor-General Order in Council At the Government House at Wellington this 5th day of June 1984 Present: His Excellency the Governor-General in Council Pursuant to section 105 of the Medicines Act 1981, and, in the case of Part 3 of the regulations, to section 62 of that Act, His Excellency the Governor-General, acting on the advice of the Minister of Health tendered after consultation with the organisations and bodies that appeared to the Minister to be representatives of persons likely to be substantially affected, and by and with the advice and consent of the Executive Coun- cil, hereby makes the following regulations. Contents Page 1 Title and commencement 5 2 Interpretation 5 Part 1 Classification of medicines 3 Classification of medicines 9 Note Changes authorised by subpart 2 of Part 2 of the Legislation Act 2012 have been made in this official reprint. Note 4 at the end of this reprint provides a list of the amendments incorporated. These regulations are administered by the Ministry of Health. 1 Reprinted as at Medicines Regulations 1984 1 December 2017 Part 2 Standards 4 Standards for medicines, related products, medical devices, 10 cosmetics, and surgical dressings 5 Pharmacist may dilute medicine in particular case 10 6 Colouring substances [Revoked] 10 Part 3 Advertisements 7 Advertisements not to claim official approval 11 8 Advertisements for medicines 11 9 Advertisements for related products 13 10 Advertisements for medical devices 13
    [Show full text]
  • Anatomical Classification Guidelines V2020 EPHMRA ANATOMICAL
    EPHMRA ANATOMICAL CLASSIFICATION GUIDELINES 2020 Anatomical Classification Guidelines V2020 "The Anatomical Classification of Pharmaceutical Products has been developed and maintained by the European Pharmaceutical Marketing Research Association (EphMRA) and is therefore the intellectual property of this Association. EphMRA's Classification Committee prepares the guidelines for this classification system and takes care for new entries, changes and improvements in consultation with the product's manufacturer. The contents of the Anatomical Classification of Pharmaceutical Products remain the copyright to EphMRA. Permission for use need not be sought and no fee is required. We would appreciate, however, the acknowledgement of EphMRA Copyright in publications etc. Users of this classification system should keep in mind that Pharmaceutical markets can be segmented according to numerous criteria." © EphMRA 2020 Anatomical Classification Guidelines V2020 CONTENTS PAGE INTRODUCTION A ALIMENTARY TRACT AND METABOLISM 1 B BLOOD AND BLOOD FORMING ORGANS 28 C CARDIOVASCULAR SYSTEM 35 D DERMATOLOGICALS 50 G GENITO-URINARY SYSTEM AND SEX HORMONES 57 H SYSTEMIC HORMONAL PREPARATIONS (EXCLUDING SEX HORMONES) 65 J GENERAL ANTI-INFECTIVES SYSTEMIC 69 K HOSPITAL SOLUTIONS 84 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS 92 M MUSCULO-SKELETAL SYSTEM 102 N NERVOUS SYSTEM 107 P PARASITOLOGY 118 R RESPIRATORY SYSTEM 120 S SENSORY ORGANS 132 T DIAGNOSTIC AGENTS 139 V VARIOUS 141 Anatomical Classification Guidelines V2020 INTRODUCTION The Anatomical Classification was initiated in 1971 by EphMRA. It has been developed jointly by Intellus/PBIRG and EphMRA. It is a subjective method of grouping certain pharmaceutical products and does not represent any particular market, as would be the case with any other classification system.
    [Show full text]